Celldex Therapeutics, Inc.
US ˙ NasdaqCM ˙ US15117B2025

SecurityCLDX / Celldex Therapeutics, Inc.
InstitutionTd Asset Management Inc
Latest Disclosed Ownership70,292 shares
Latest Disclosed Value $ 2,229,662
Td Asset Management Inc reports 5.59% increase in ownership of CLDX / Celldex Therapeutics, Inc.

On May 11, 2026 - Td Asset Management Inc filed a 13F-HR form disclosing ownership of 70,292 shares of Celldex Therapeutics, Inc. (US:CLDX) valued at $2,229,662 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 66,570 shares of Celldex Therapeutics, Inc.. This represents a change in shares of 5.59% during the quarter. The current value of the position is $2,011,757 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 70,292 3,722 5.59 2,230 23.29 0.0010
2026-02-10 2025-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 66,570 -25,880 -27.99 1,808 -24.38 0.0015
2025-11-10 2025-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 92,450 -35,428 -27.70 2,392 -8.11 0.0019
2025-07-28 2025-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 127,878 49,000 62.12 2,602 81.83 0.0022
2025-05-07 2025-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 78,878 -65,000 -45.18 1,432 -60.63 0.0013
2025-02-11 2024-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 143,878 -20,200 -12.31 3,636 -33.27 0.0032
2024-11-01 2024-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 164,078 -25,600 -13.50 5,447 -22.40 0.0048
2024-08-02 2024-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 189,678 -35,800 -15.88 7,020 -25.83 0.0065
2024-05-08 2024-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 225,478 173,156 330.94 9,463 356.05 0.0088
2024-02-12 2023-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 52,322 -12,600 -19.41 2,075 16.18 0.0020
2023-10-27 2023-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 64,922 32,461 100.00 1,787 62.22 0.0022
2023-08-09 2023-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 32,461 -13,300 -29.06 1,101 -33.11 0.0013
2023-05-10 2023-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 45,761 -9,500 -17.19 1,646 -33.14 0.0020
2023-02-07 2022-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 55,261 7,600 15.95 2,463 82.24 0.0030
2022-11-07 2022-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 47,661 11,000 30.00 1,351 36.74 0.0017
2022-08-04 2022-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 36,661 -37,168 -50.34 988 -60.72 0.0011
2022-05-10 2022-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 73,829 11,500 18.45 2,515 4.44 0.0015
2022-02-10 2021-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 62,329 0 0.00 2,408 -28.44 0.0020
2021-11-09 2021-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 62,329 17,400 38.73 3,365 71.16 0.0035
2021-08-11 2021-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 44,929 22,079 96.63 1,966 317.41 0.0020
2021-05-14 2021-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 22,850 6,450 39.33 471 64.11 0.0005
2021-02-16 2020-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 16,400 16,400 287 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.